annamycin (BioDeep_00000781232)
代谢物信息卡片
化学式: C26H25IO11 (640.0441569999999)
中文名称: (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-二羟基-3-碘-6-甲基氧杂环己-2-基]氧基-6,9,11-三羟基-9-(2-羟基乙酰基)-8,10-二氢-7H-并四苯-5,12-二酮
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1C(C(C(C(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)CO)O)I)O)O
InChI: InChI=1S/C26H25IO11/c1-9-19(30)24(35)18(27)25(37-9)38-13-7-26(36,14(29)8-28)6-12-15(13)23(34)17-16(22(12)33)20(31)10-4-2-3-5-11(10)21(17)32/h2-5,9,13,18-19,24-25,28,30,33-36H,6-8H2,1H3/t9-,13-,18+,19-,24-,25-,26-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hsin-I Chang, Ming-Kung Yeh. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.
International journal of nanomedicine.
2012; 7(?):49-60. doi:
10.2147/ijn.s26766. [PMID: 22275822] - Débora B Vieira, Ana M Carmona-Ribeiro. Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro.
Journal of nanobiotechnology.
2008 May; 6(?):6. doi:
10.1186/1477-3155-6-6. [PMID: 18462496] - Maria Laura Immordino, Franco Dosio, Luigi Cattel. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
International journal of nanomedicine.
2006; 1(3):297-315. doi:
". [PMID: 17717971] - D J Booser, R Perez-Soler, P Cossum, L Esparza-Guerra, Q P Wu, Y Zou, W Priebe, G N Hortobagyi. Phase I study of liposomal annamycin.
Cancer chemotherapy and pharmacology.
2000; 46(5):427-32. doi:
10.1007/s002800000177. [PMID: 11127949] - K M Wasan, S Ng, S M Cassidy. Modifications in high-density lipoprotein lipid composition and structure alter the plasma distribution of free and liposomal annamycin.
Journal of pharmaceutical sciences.
1997 Jul; 86(7):872-5. doi:
10.1021/js960495j. [PMID: 9232531] - K M Wasan, M Kwong. Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin.
Pharmacology & toxicology.
1997 Jun; 80(6):301-7. doi:
10.1111/j.1600-0773.1997.tb01978.x. [PMID: 9225368] - K M Wasan, G Lopez-Berestein. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
1996 Nov; 23(5):1126-38. doi:
10.1093/clinids/23.5.1126. [PMID: 8922813] - U Consoli, W Priebe, Y H Ling, R Mahadevia, M Griffin, S Zhao, R Perez-Soler, M Andreeff. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Blood.
1996 Jul; 88(2):633-44. doi:
10.1182/blood.v88.2.633.bloodjournal882633. [PMID: 8695811] - K M Wasan, R E Morton. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.
Pharmaceutical research.
1996 Mar; 13(3):462-8. doi:
10.1023/a:1016065114515. [PMID: 8692743] - Y Zou, W Priebe, R Perez-Soler. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size.
Cancer chemotherapy and pharmacology.
1996; 39(1-2):103-8. doi:
10.1007/s002800050544. [PMID: 8995506] - Y Zou, W Priebe, L C Stephens, R Perez-Soler. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1995 Nov; 1(11):1369-74. doi:
". [PMID: 9815933] - K M Wasan, R Perez-Soler. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.
Journal of pharmaceutical sciences.
1995 Sep; 84(9):1094-100. doi:
10.1002/jps.2600840912. [PMID: 8537888] - Y Zou, Y H Ling, S Reddy, W Priebe, R Perez-Soler. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes.
International journal of cancer.
1995 May; 61(5):666-71. doi:
10.1002/ijc.2910610513. [PMID: 7768640] - Y Zou, A Hayman, W Priebe, R Perez-Soler. Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography.
Journal of pharmaceutical sciences.
1993 Nov; 82(11):1151-4. doi:
10.1002/jps.2600821117. [PMID: 8289131] - Y H Ling, W Priebe, L Y Yang, T G Burke, Y Pommier, R Perez-Soler. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Cancer research.
1993 Apr; 53(7):1583-9. doi:
". [PMID: 8453627] - Y Zou, W Priebe, Y H Ling, R Perez-Soler. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.
Cancer chemotherapy and pharmacology.
1993; 32(3):190-6. doi:
10.1007/bf00685834. [PMID: 8500223]
